News & Publications

News

Deals & Cases

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion

9 December 2020 – Walder Wyss advises Boehringer Ingelheim in the acquisition of NBE-Therapeutics AG. NBE-Therapeutics is a private Basel based clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors.

The total transaction value is EUR 1.18 billion and also includes contingent clinical and regulatory milestones.

The consummation of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021.

The Walder Wyss team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and included Robert Desax (Partner, Tax), Jessica Aeschbach Flórez (Senior Associate, Corporate/M&A), Karina Tschon (Associate, Corporate/M&A and Venture Capital), Flurin Vionnet-Riederer (Associate, Corporate/M&A), Christoph Burckhardt (Associate, Corporate/M&A) and Jonas Knechtli (Senior Associate, Employment).

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.